4t1 metastatic mice breast tumor cell line Search Results


99
ATCC mouse breast cancer 4t1 cells
Mouse Breast Cancer 4t1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pm24362525-103-9-20?v=ATCC
Average 99 stars, based on 1 article reviews
mouse breast cancer 4t1 cells - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

94
ATCC mouse mammary carcinoma cell line 4t1
Mouse Mammary Carcinoma Cell Line 4t1, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pm19088425-33-40-46?v=ATCC
Average 94 stars, based on 1 article reviews
mouse mammary carcinoma cell line 4t1 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

99
ATCC mouse mammary gland breast epithelial cell line 4t1
Effect of resveratrol on the cell viability of MCF-7 and MDA-MB-231 cells. ( a ) <t>4T1,</t> ( b ) MCF-7 and ( c ) MDA-MB-231 cells (2 × 10 5 ) were incubated in the presence of different concentrations (10 to 300 μM) of resveratrol, or 0.1% DMSO (control), for 24 h at 37 °C. They were then washed and maintained with MTT (0.5 mg/mL) for 3 h at 37 °C for formazan crystals formation and the associated optical density was analyzed at 570 and 650 nm. The results were expressed as mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different (p < 0.05) from the values corresponding to the control, using One-way ANOVA, followed by multiple comparison test Dunnett.
Mouse Mammary Gland Breast Epithelial Cell Line 4t1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc06764983-135-12-22?v=ATCC
Average 99 stars, based on 1 article reviews
mouse mammary gland breast epithelial cell line 4t1 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

90
China Center for Type Culture Collection mouse mammary tumor cells 4t1
Effect of resveratrol on the cell viability of MCF-7 and MDA-MB-231 cells. ( a ) <t>4T1,</t> ( b ) MCF-7 and ( c ) MDA-MB-231 cells (2 × 10 5 ) were incubated in the presence of different concentrations (10 to 300 μM) of resveratrol, or 0.1% DMSO (control), for 24 h at 37 °C. They were then washed and maintained with MTT (0.5 mg/mL) for 3 h at 37 °C for formazan crystals formation and the associated optical density was analyzed at 570 and 650 nm. The results were expressed as mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different (p < 0.05) from the values corresponding to the control, using One-way ANOVA, followed by multiple comparison test Dunnett.
Mouse Mammary Tumor Cells 4t1, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc07001653-258-22-30?v=China+Center+for+Type+Culture+Collection
Average 90 stars, based on 1 article reviews
mouse mammary tumor cells 4t1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Sinopharm ltd sinopharm vaccine
Effect of resveratrol on the cell viability of MCF-7 and MDA-MB-231 cells. ( a ) <t>4T1,</t> ( b ) MCF-7 and ( c ) MDA-MB-231 cells (2 × 10 5 ) were incubated in the presence of different concentrations (10 to 300 μM) of resveratrol, or 0.1% DMSO (control), for 24 h at 37 °C. They were then washed and maintained with MTT (0.5 mg/mL) for 3 h at 37 °C for formazan crystals formation and the associated optical density was analyzed at 570 and 650 nm. The results were expressed as mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different (p < 0.05) from the values corresponding to the control, using One-way ANOVA, followed by multiple comparison test Dunnett.
Sinopharm Vaccine, supplied by Sinopharm ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pm36907328-133-0-11?v=Sinopharm+ltd
Average 90 stars, based on 1 article reviews
sinopharm vaccine - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

86
Jackson Laboratory 4t1 mouse breast cancer model
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
4t1 Mouse Breast Cancer Model, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc09841600-74-3-15?v=Jackson+Laboratory
Average 86 stars, based on 1 article reviews
4t1 mouse breast cancer model - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

90
NanoVector hfn nanovector
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
Hfn Nanovector, supplied by NanoVector, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc05352408__oncotarget___08___8383___s001-50-5-8?v=NanoVector
Average 90 stars, based on 1 article reviews
hfn nanovector - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

99
ATCC mouse breast cancer cell line 4t1
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
Mouse Breast Cancer Cell Line 4t1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pm36818419-249-12-21?v=ATCC
Average 99 stars, based on 1 article reviews
mouse breast cancer cell line 4t1 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

95
ATCC 4t1 2 mouse mammary tumor cells
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
4t1 2 Mouse Mammary Tumor Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc05823640-128-0-13?v=ATCC
Average 95 stars, based on 1 article reviews
4t1 2 mouse mammary tumor cells - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

90
AstraZeneca ltd astrazeneca a1/a2
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
Astrazeneca A1/A2, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc10007716-18-16-12?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
astrazeneca a1/a2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

96
ATCC t1 luc2 mouse breast cancer cells
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
T1 Luc2 Mouse Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc09798675-73-2-7?v=ATCC
Average 96 stars, based on 1 article reviews
t1 luc2 mouse breast cancer cells - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

93
Selleck Chemicals 4t1 bearing mice
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
4t1 Bearing Mice, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4t1+metastatic+mice+breast+tumor+cell+line/pmc10352264-345-8-17?v=Selleck+Chemicals
Average 93 stars, based on 1 article reviews
4t1 bearing mice - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


Effect of resveratrol on the cell viability of MCF-7 and MDA-MB-231 cells. ( a ) 4T1, ( b ) MCF-7 and ( c ) MDA-MB-231 cells (2 × 10 5 ) were incubated in the presence of different concentrations (10 to 300 μM) of resveratrol, or 0.1% DMSO (control), for 24 h at 37 °C. They were then washed and maintained with MTT (0.5 mg/mL) for 3 h at 37 °C for formazan crystals formation and the associated optical density was analyzed at 570 and 650 nm. The results were expressed as mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different (p < 0.05) from the values corresponding to the control, using One-way ANOVA, followed by multiple comparison test Dunnett.

Journal: Scientific Reports

Article Title: Increase in fatty acids and flotillins upon resveratrol treatment of human breast cancer cells

doi: 10.1038/s41598-019-50416-5

Figure Lengend Snippet: Effect of resveratrol on the cell viability of MCF-7 and MDA-MB-231 cells. ( a ) 4T1, ( b ) MCF-7 and ( c ) MDA-MB-231 cells (2 × 10 5 ) were incubated in the presence of different concentrations (10 to 300 μM) of resveratrol, or 0.1% DMSO (control), for 24 h at 37 °C. They were then washed and maintained with MTT (0.5 mg/mL) for 3 h at 37 °C for formazan crystals formation and the associated optical density was analyzed at 570 and 650 nm. The results were expressed as mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different (p < 0.05) from the values corresponding to the control, using One-way ANOVA, followed by multiple comparison test Dunnett.

Article Snippet: The human mammary gland/breast epithelial cell lines MCF-7 and MDA-MB-231, and the mouse mammary gland/breast epithelial cell line 4T1 were obtained from American Type Culture Collection (ATCC® HTB-22TM, HTB-26TM and CLR-2539TM respectively).

Techniques: Incubation, Control, Comparison

Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of 4T1 tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of 4T1 tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: Imaging, Injection, Fluorescence, Ex Vivo

Intravital imaging of Cy5-FUD and Cy5-PEG-FUD in 4T1 mouse mammary carcinoma. After two weeks of tumor growth, images were acquired pre and post- 24 h SC injection of Cy5- peptides. SHG (collagen fibers) shown in grey, Cy5 (peptide) shown in cyan and vasculature in red. (A) Representative image of Cy5-FUD and Cy5-PEG-FUD in the TME pre-injection and 24 h post-injection, respectively. Scale bar = 150 μm. (B) Quantification of mean intensity of Cy5-labeled peptides. (C) Zoomed inset of Cy5-PEG-FUD 24 h p.i. Yellow arrows indicate Cy5-peptides localizing to cellular structures. Scale bar = 50 μm, ns: non-significant, ***: P < 0.001.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: Intravital imaging of Cy5-FUD and Cy5-PEG-FUD in 4T1 mouse mammary carcinoma. After two weeks of tumor growth, images were acquired pre and post- 24 h SC injection of Cy5- peptides. SHG (collagen fibers) shown in grey, Cy5 (peptide) shown in cyan and vasculature in red. (A) Representative image of Cy5-FUD and Cy5-PEG-FUD in the TME pre-injection and 24 h post-injection, respectively. Scale bar = 150 μm. (B) Quantification of mean intensity of Cy5-labeled peptides. (C) Zoomed inset of Cy5-PEG-FUD 24 h p.i. Yellow arrows indicate Cy5-peptides localizing to cellular structures. Scale bar = 50 μm, ns: non-significant, ***: P < 0.001.

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: Imaging, Injection, Labeling

(A) A schematic diagram of the experimental design of μPET/CT imaging. (B) Longitudinal PET images of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD (5 mg/kg). The images were acquired 2, 24, and 48 h p.i. The white arrows indicate the locations of the major organs, i.e., tumor, heart, liver, and kidneys. Fig. 7A created with BioRender.com .

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: (A) A schematic diagram of the experimental design of μPET/CT imaging. (B) Longitudinal PET images of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD (5 mg/kg). The images were acquired 2, 24, and 48 h p.i. The white arrows indicate the locations of the major organs, i.e., tumor, heart, liver, and kidneys. Fig. 7A created with BioRender.com .

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: Imaging, IV Injection

(A) In vivo μPET imaging analysis of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD shown in time-activity curves for heart, lung, tumor, kidneys, and liver (means ± SD, n = 4). (B) Analysis of ex vivo biodistribution of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD after IV injection. The activity remaining in organs at each time point at 48 h was presented as the percent injected activity per gram (%IA/g). *: P < 0.05, **: P <0.01, ***: P <

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: (A) In vivo μPET imaging analysis of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD shown in time-activity curves for heart, lung, tumor, kidneys, and liver (means ± SD, n = 4). (B) Analysis of ex vivo biodistribution of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD after IV injection. The activity remaining in organs at each time point at 48 h was presented as the percent injected activity per gram (%IA/g). *: P < 0.05, **: P <0.01, ***: P <

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: In Vivo, Imaging, IV Injection, Activity Assay, Ex Vivo, Injection